These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26367749)

  • 41. Topical immunotherapy with contact sensitizers: a model to study the natural history of delayed hypersensitivity.
    Mastrolonardo M; Lopalco PL; Diaferio A
    Contact Dermatitis; 2002 Oct; 47(4):210-4. PubMed ID: 12492519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermodysplasia Verruciformis After Hematopoietic Stem Cell Transplantation in a Patient With Severe Combined Immunodeficiency Syndrome.
    Bostan E; Akdogan N; Gokoz O
    Am J Dermatopathol; 2021 May; 43(5):e65-e67. PubMed ID: 33577180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pathogenesis of human papillomavirus infection in patients with epidermodysplasia verruciformis].
    Liang S; Zuo YG; Wang BX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):93-6. PubMed ID: 19317070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. What is the evidence for effective treatments of acquired epidermodysplasia verruciformis in HIV-infected patients?
    Lee KC; Risser J; Bercovitch L
    Arch Dermatol; 2010 Aug; 146(8):903-5. PubMed ID: 20713825
    [No Abstract]   [Full Text] [Related]  

  • 45. [Squaric acid dibutyl ester in the treatment of severe alopecia areata].
    Miranda A; Mato F; Quiñones PA
    Med Cutan Ibero Lat Am; 1984; 12(3):273-8. PubMed ID: 6384701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod.
    Nijhawan RI; Osei-Tutu A; Hugh JM
    J Drugs Dermatol; 2013 Mar; 12(3):348-9. PubMed ID: 23545921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidermodysplasia verruciformis.
    Dyall-Smith D; Cowen P; Varigos G
    Australas J Dermatol; 1989; 30(2):81-5. PubMed ID: 2486177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidermodysplasia verruciform-like Lesions in an HIV patient.
    Berk DR; Bruckner AL; Lu D
    Dermatol Online J; 2009 Jan; 15(1):1. PubMed ID: 19281706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA.
    Weissenborn SJ; Höpfl R; Weber F; Smola H; Pfister HJ; Fuchs PG
    J Invest Dermatol; 1999 Jul; 113(1):122-6. PubMed ID: 10417630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multifocal leiomyosarcomatosis in a 6-year-old child with epidermodysplasia verruciformis and immune defect.
    Boybeyi O; Akçören Z; Oğuz B; Akyüz C; Sanal O; Ergin S; Ersoy-Evans S; Tanyel FC
    J Pediatr Surg; 2009 Jul; 44(7):e5-8. PubMed ID: 19573649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidermodysplasia verruciformis associated with plasmablastic lymphoma and hepatitis B virus infection.
    Shayanfar N; Babaheidarian P; Rahmani H; Azadmanesh K; Sohrabi A; Mohammadpour M; Mirzaie AZ; Parvaneh N
    Acta Dermatovenerol Croat; 2012; 20(4):267-71. PubMed ID: 23317490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Polyclonal antibody to human papillomavirus-related antigens specific to epidermodysplasia verruciformis].
    Ishiji T
    Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):683-95. PubMed ID: 2479785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses.
    Orth G
    Semin Immunol; 2006 Dec; 18(6):362-74. PubMed ID: 17011789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topical immunotherapy in dermatology.
    Buckley DA; du Vivier AW
    Int J Clin Pract; 1999 Mar; 53(2):130-7. PubMed ID: 10344049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of in vivo dose response and allergen-specific T cells in subjects contact-sensitized to squaric acid dibutyl ester.
    Camouse MM; Swick AR; Ryan CA; Hulette B; Gerberick F; Tinkle SS; Nedorost ST; Cooper KD; Stevens SR; Baron ED
    Dermatitis; 2008; 19(2):95-9. PubMed ID: 18413111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermodysplasia verruciformis: report of a case with palmar pits.
    Galadari I; Abdul Aal J
    Cutis; 1993 Jul; 52(1):53-5. PubMed ID: 8354088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Four familial cases of epidermodysplasia verruciformis: mother and three sons.
    Robati RM; Marefat A; Saeedi M; Rahmati-Roodsari M; Asadi-Kani Z
    Dermatol Online J; 2009 Apr; 15(4):8. PubMed ID: 19450401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Seborrheic Keratosis-like lesions in patients with epidermodysplasia verruciformis.
    Roncalli de Oliveira W; Neto CF; Rady PL; Tyring SK
    J Dermatol; 2003 Jan; 30(1):48-53. PubMed ID: 12598709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deleterious Effect of Radiation Therapy on Epidermodysplasia Verruciformis Patients.
    de Oliveira WR; da Cruz Silva LL; Neto CF; Tyring S
    J Cutan Med Surg; 2015; 19(4):416-21. PubMed ID: 26156649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis.
    Dell'Oste V; Azzimonti B; De Andrea M; Mondini M; Zavattaro E; Leigheb G; Weissenborn SJ; Pfister H; Michael KM; Waterboer T; Pawlita M; Amantea A; Landolfo S; Gariglio M
    J Invest Dermatol; 2009 Apr; 129(4):1026-34. PubMed ID: 18923444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.